Denna sida på svenska

Christina Hammarstedt

Biomedical scientist

Visiting address : Lab 517 Hematologlab; Novum, plan 5, Lab 517; Hälsovägen 7-9, 14157 Huddinge, Sweden
Postal address : Department of Laboratory Medicine (LABMED), H5, Division of Pathology, Lab 517 Hermatoglab; Novum, plan 5, Lab 517; Hälsovägen 7-9, 14157 Huddinge, Sweden
Delivery address : KFC, Hematologlab, Novum, plan 5, Lab 517; Karolinska Universitetssjukhuset Huddinge; Vårdarvägen 1, 14152 Huddinge, Sweden

Publications

NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation
Bjorklund At, Schaffer M, Fauriat C, Ringden O, Remberger M, Hammarstedt C, et al
BLOOD 2010;115(13):2686-94

Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34(+) blasts in myelodysplastic syndrome
Carlsten M, Baumann Bc, Simonsson M, Jadersten M, Forsblom Am, Hammarstedt C, et al
LEUKEMIA 2010;24(9):1607-16

Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: A comparative study between the standard 4-dose and a 2-dose regimen
Mellgren K, Nilsson C, Fasth A, Abrahamsson J, Winiarski J, Ringden O, et al
BONE MARROW TRANSPLANTATION 2008;41(7):621-5

Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro
Song Hr, Vita M, Sallam H, Tehranchi R, Nilsson C, Siden A, et al
CANCER CHEMOTHERAPY AND PHARMACOLOGY 2007;60(6):841-9

The effect of repeated administration of cyclophosphamide on cytochrome P4502B in rats
Afsharian P, Ylva Tz, Hassan Z, Nilsson C, Lundgren S, Hassan M
CLINICAL CANCER RESEARCH 2007;13(14):4218-24

CMV-specific T-cell immunity after allogeneic SCT
Avetisyan G, Larsson K, Nilsson C, Hassan M, Ljungman P
BONE MARROW TRANSPLANTATION 2006;:S172-S172

Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation
Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P
BONE MARROW TRANSPLANTATION 2006;38(10):687-92

Myeloablative and immunosuppressive properties of treosulfan in mice
Sjoo F, Hassan Z, Abedi-valugerdi M, Griskevicius L, Nilsson C, Remberger M, et al
EXPERIMENTAL HEMATOLOGY 2006;34(1):115-21

Safe administration of oral busulphan b.i.d during conditioning for stem cell transplantation in a paediatric population - a comparative study between the standard 4-dose regimen and a 2-dose regimen
Mellgren K, Nilsson C, Fasth A, Abrahamsson J, Soderhall S, Winiarski J, et al
BONE MARROW TRANSPLANTATION 2006;:S204-S204

Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury-induced autoimmunity and exacerbates such autoimmunity in susceptible mice
Abedi-valugerdi M, Nilsson C, Zargari A, Gharibdoost F, Depierre Jw, Hassan M
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 2005;141(2):238-47

Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice
Nilsson C, Forsman J, Hassan Z, Abedi-valugerdi M, O'connor C, Concha H, et al
EXPERIMENTAL HEMATOLOGY 2005;33(3):380-7

Stability, pKa and plasma protein binding of roscovitine
Vita M, Abdel-rehim M, Nilsson C, Hassan Z, Skansen P, Wan H, et al
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 2005;821(1):75-80

The influence of administration order of busulphan and cyclophosphamide on dendritic cells in stem cell transplantation mouse model
Nilsson C, Forsman J, Cussen E, Hassan Z, Abedi-valugerdi Ma, Concha H, et al
BONE MARROW TRANSPLANTATION 2005;:S140-S140

The effect of administration order of busulphan and cyclophosphamide on the myeloblative and immunosuppressive properties of the conditioning regimen
Nilsson C, Forsman J, O'connor C, Concha H, Hassan M
BONE MARROW TRANSPLANTATION 2004;:S308-S308

The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation
Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman P, Hassan M
BONE MARROW TRANSPLANTATION 2003;31(6):429-35

Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study
Ljungman P, Wang Fz, Nilsson C, Solheim V, Linde A
SUPPORTIVE CARE IN CANCER 2003;11(11):739-41

A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning
Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, et al
BONE MARROW TRANSPLANTATION 2002;30(12):833-41

Pharmacokinetics of liposomal busulphan in man
Hassan Z, Ljungman P, Ringden O, Winiarski J, Nilsson C, Aschan J, et al
BONE MARROW TRANSPLANTATION 2001;27(5):479-85

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients
Sandstrom M, Karlsson Mo, Ljungman P, Hassan Z, Jonsson En, Nilsson C, et al
BONE MARROW TRANSPLANTATION 2001;28(7):657-64

The meyloablative and immunosuppressive properties of treosulfan in mice.
Griskevicius L, Gaughan U, Canaparo R, Nilsson C, Hassan M
BLOOD 2001;98(11):316B-316B

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation
Olavarria E, Hassan M, Eades A, Nilsson C, Timms A, Matthews J, et al
LEUKEMIA 2000;14(11):1954-9

Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy
Hassan M, Svensson Jo, Nilsson C, Hentschke P, Al-shurbaji A, Aschan J, et al
THERAPEUTIC DRUG MONITORING 2000;22(4):383-5

Pharmacokinetics of liposomal busulfan in man.
Hassan Z, Ljungman P, Ringden O, Winiarski J, Nilsson C, Aschan J, et al
BLOOD 2000;96(11):387A-387A

Phase I clinical trial of liposomal busulphan.
Hassan M, Nilsson C, Ljungman P, Hassau Z, Ringden O, Hentschke P, et al
BLOOD 2000;96(11):388A-388A

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity
Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C, et al
BONE MARROW TRANSPLANTATION 2000;25(9):915-24

A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients
Hassan M, Svensson Ush, Ljungman P, Bjorkstrand B, Olsson H, Bielenstein M, et al
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 1999;48(5):669-77

In vivo dynamic distribution of I-131-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera
Hassan M, Eskilsson A, Nilsson C, Jonsson C, Jacobsson H, Refai E, et al
NUCLEAR MEDICINE AND BIOLOGY 1999;26(4):413-20

Liposomal busulphan - Pharmacokinetics in mouse, rat and man.
Hassan M, Ljungman P, Ringden O, Hassan Z, Nilsson C
BONE MARROW TRANSPLANTATION 1999;:S73-S73

Pharmacokinetics of cyclophosphamide and its 4-hydroxy cyclophosphamide in breast cancer patients: A pharmacokinetic model involving enzyme induction.
Hassan M, Ljungman P, Svensson U, Bjorkstrand B, Nilsson C, Karlsson M
BONE MARROW TRANSPLANTATION 1999;:S40-S40

The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma
Hassan M, Nilsson C, Olsson H, Lundin J, Osterborg A
EUROPEAN JOURNAL OF HAEMATOLOGY 1999;63(3):163-70

The pharmacokinetics of low dose of liposomal busulphan in man.
Hassan M, Ljungman P, Ringden O, Hassan Z, Nilsson C
BLOOD 1999;94(10):150A-150A

Liposomal busulphan: bioavailability and effect on bone marrow in mice
Hassan Z, Nilsson C, Hassan M
BONE MARROW TRANSPLANTATION 1998;22(9):913-8

Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration
Hassan M, Hassan Z, Nilsson C, Rehim Ma, Kumlien S, Elfsson B, et al
CANCER CHEMOTHERAPY AND PHARMACOLOGY 1998;42(6):471-8

The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in myeloma patients.
Hassan M, Olsson H, Lundin J, Nilsson C, Osterborg A
BLOOD 1998;92(10):277B-277B

Show all publications